Lung cancer test kit VANGUARD™

oncologyplasmaliquid biopsy

Lung cancer has the most established targeted therapy treatment landscape. Targeting specific genetic mutations, such as EGFR and BRAF mutations, ALK, ROS1 and NTRK gene rearrangements with drugs provides specificity towards cancer cells while sparing toxicity to normal cells and ultimately improving patient outcomes. Therefore, genetic testing is a crucial step in matching a patient to the right targeted therapy. Our lung cancer-specific panels can meet all of your clinical needs for lung cancer patients at all disease stages. Optional PD-L1 immunohistochemistry (IHC) test is available to better guide immunotherapy decisions. DEPTH Now MATTERS Minimally invasive approach: only 8-10mL of peripheral blood needed to test 139 key genes in lung cancer ATG-seq technology combines 30,000x deep-sequencing and state-of-art background noise reduction technology to achieve ultra-high detection sensitivity and specificity in liquid biopsy WHO IS IT FOR Applicable to entire course of disease in lung cancer (Vanguard™ Dynamic Monitoring )